ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS) Files An 8-K Other Events
Item 8.01 Other Events.
On December 12, 2019, Daniel J. O’Connor, President, CEO and Director of OncoSec Medical Incorporated (“OncoSec” or the “Company”), issued a letter to shareholders and related press release regarding the upcoming special meeting of stockholders of the Company scheduled to be held on January 17, 2020 to vote on a proposed strategic transaction with Grand Decade Developments Limited, a British Virgin Islands limited company and a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited and its U.S. affiliate, Sirtex Medical US Holdings, Inc.
A copy of the press release that includes the letter to OncoSec shareholders is furnished as Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits.
The following exhibit is furnished as part of this report:
| Exhibit Number | Description |
| 99.1 | Press Release dated December 12, 2019. |
ONCOSEC MEDICAL Inc Exhibit
EX-99.1 2 ex99-1.htm OncoSec CEO Sends Letter to Fellow Shareholders Explains Crucial Importance of Strategic Transaction and Partnership with CGP and Sirtex Immediate $30 Million Cash Infusion at a Premium Provides Pathway to Unlock Value of TAVO and OncoSec’s Entire Platform Transaction is Optimal Way to Deliver Improved Value for Shareholders Vote “FOR” the CGP/Sirtex Transaction on the WHITE Proxy Card Today SAN DIEGO and PENNINGTON,…
To view the full exhibit click here
About ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS)
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.